









Markets
/
Stocks
/
nasdaq-sttk
/

Shattuck Labs Inc

STTK

5.990USD

-0.320-5.07%

Market hours （ET）Quotes delayed by 15 min

228.10MMarket Cap

LossP/E TTM



Shattuck Labs Inc

5.990

-0.320-5.07%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Shattuck Labs Inc

Currency: USD Updated: 2026-03-27

Key Insights

Shattuck Labs Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 55 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.00.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Shattuck Labs Inc's Score

Industry at a Glance

Industry Ranking

55 / 391

Overall Ranking

162 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Shattuck Labs Inc Highlights

StrengthsRisks

Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.

Growing

The company is in a growing phase, with the latest annual income totaling USD 1.00M.

Undervalued

The company’s latest PE is -8.58, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 35.93M shares, increasing 10.06% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 340.70K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 6.26.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

10.000

Target Price

+58.48%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Shattuck Labs Inc is 7.66, ranking 75 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.66

Change



Financials

9.61

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.01

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

3.14

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.54

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Shattuck Labs Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Shattuck Labs Inc is 6.80, ranking 217 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -8.58, which is -93.85% below the recent high of -0.53 and -5.81% above the recent low of -9.08.

Score

Industry at a Glance

Previous score

6.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 55/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Shattuck Labs Inc is 7.71, ranking 270 out of 391 in the Biotechnology & Medical Research industry. The average price target is 4.00, with a high of 6.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

8.00

Change

-0.29

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

10.000

Target Price

+58.48%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Shattuck Labs Inc

STTK

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Shattuck Labs Inc is 9.33, ranking 12 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 7.28 and the support level at 4.28, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.52

Change

-0.19

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.055

Neutral

RSI(14)

63.168

Neutral

STOCH(KDJ)(9,3,3)

44.798

Sell

ATR(14)

0.387

Low Volatility

CCI(14)

-3.041

Neutral

Williams %R

63.185

Sell

TRIX(12,20)

1.628

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

6.188

Sell

MA10

6.127

Sell

MA20

5.765

Buy

MA50

4.747

Buy

MA100

3.825

Buy

MA200

2.604

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Shattuck Labs Inc is 5.00, ranking 136 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 56.78%, representing a quarter-over-quarter increase of 9.79%. The largest institutional shareholder is The Vanguard, holding a total of 2.38M shares, representing 3.32% of shares outstanding, with 33.70% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

OrbiMed Advisors, LLC

6.31M

Adage Capital Management, L.P.

6.31M

+34.89%

Redmile Group, LLC

5.54M

Hornblower Capital Holdings, LLC

2.89M

Houghton Capital Holdings, LLC

2.61M

Prosight Capital

5.45M

-17.89%

The Vanguard Group, Inc.

Star Investors

2.13M

-0.92%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Shattuck Labs Inc is 2.30, ranking 233 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 1.37. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.